Social networks
3,201Activities
Technologies
Entity types
Location
1015 Lausanne, Switzerland
Lausanne
Switzerland
Employees
Scale: 11-50
Estimated: 38
Engaged corporates
3Added in Motherbase
1 year, 1 month agoOculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
pharmaceutical, ophthalmology, drug delivery, and Biotech
Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
McKinsey & Company Consulting, Business Consulting and Services | McKinsey & Company Consulting, Business Consulting and Services | Other 30 Sep 2023 | | |
EPFL Innovation Park Startup accelerator & VC, Professional Training and Coaching | EPFL Innovation Park Startup accelerator & VC, Professional Training and Coaching | Other 11 Jun 2023 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 5 Jun 2023 | |